MMTZFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as RLFTY
MindMaze Therapeutics Holding SA
Financials through fiscal 2023, year ended Dec 31, 2023Last filing: 20-F on Apr 30, 2024
$0.19−0.00 (-0.22%)
Close on Oct 19, 2026
MindMaze Therapeutics statistics
Financials through Dec 31, 2023, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Market Cap | CHF 2.01M | CHF 62.39M |
| Enterprise Value | -CHF 12.20M | CHF 27.59M |
| PS Ratio | 0.32 |
Enterprise value
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -1.93 |
Income (trailing twelve months)
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Revenue | CHF 6.33M | |
| Operating Income | -CHF 110.83M | -CHF 69.32M |
| Pretax Income | -CHF 111.68M | -CHF 70.45M |
| EBITDA | -CHF 107.51M | -CHF 69.32M |
| EPS (Diluted) | -8.35 CHF | -1.65 CHF |
Margins
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -1751.4% | |
| Pretax Margin | -1764.9% | |
| EBITDA Margin | -1699.0% | |
| FCF Margin | -285.4% |
Returns
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -159.5% | -133.0% |
Growth
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -11.0% |
Balance sheet
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | CHF 14.56M | CHF 27.76M |
| Total Debt | CHF 346.00K | |
| Net Cash (Debt) | CHF 14.21M | CHF 27.76M |
| Net Cash Per Share | 1.13 CHF | 1.03 CHF |
| Working Capital | CHF 11.40M | CHF 11.40M |
Financial position
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.65 | 2.65 |
| Quick Ratio | 2.28 | 2.21 |
| Interest Coverage | -116.78 | -116.78 |
Cash flow (trailing twelve months)
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -CHF 17.61M | -CHF 51.26M |
| Capital Expenditures | -CHF 446.00K | -CHF 446.00K |
| Free Cash Flow | -CHF 18.06M | -CHF 51.97M |
| FCF Per Share | -1.44 CHF | -1.11 CHF |
Efficiency
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.05 | |
| Revenue Per Employee | CHF 129.14K | |
| Employee Count | 49 | 49 |
Dividends and yields
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| FCF Yield | -898.1% | -42.3% |
| Buyback Yield | -249.4% | |
| Shareholder Yield | -249.4% |
Shares
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 12,540,400 | 50,231,950 |
| Shares Change (YoY) | 11.2% | 10.4% |
| Float | 12,540,400 | 41,812,550 |
| Shares Held by Insiders | 0.00% | 19.3% |
Taxes
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Income Tax | -CHF 13.50M | CHF 0 |
Scores
| Measure | MindMaze Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -4.48 | -4.48 |
Calculated by StockData from MindMaze Therapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.